BRPI1010035A2 - Células deficientes em fucosilação - Google Patents

Células deficientes em fucosilação

Info

Publication number
BRPI1010035A2
BRPI1010035A2 BRPI1010035-0A BRPI1010035A BRPI1010035A2 BR PI1010035 A2 BRPI1010035 A2 BR PI1010035A2 BR PI1010035 A BRPI1010035 A BR PI1010035A BR PI1010035 A2 BRPI1010035 A2 BR PI1010035A2
Authority
BR
Brazil
Prior art keywords
fucosylation
deficient cells
deficient
cells
Prior art date
Application number
BRPI1010035-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Gang Chen
Darya Burakov
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI1010035A2 publication Critical patent/BRPI1010035A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271GDP-L-fucose synthase (1.1.1.271)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1010035-0A 2009-06-02 2010-06-01 Células deficientes em fucosilação BRPI1010035A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27
PCT/US2010/036914 WO2010141478A1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (1)

Publication Number Publication Date
BRPI1010035A2 true BRPI1010035A2 (pt) 2015-08-25

Family

ID=42338231

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010035-0A BRPI1010035A2 (pt) 2009-06-02 2010-06-01 Células deficientes em fucosilação

Country Status (16)

Country Link
US (8) US8409838B2 (enExample)
EP (3) EP2438171B1 (enExample)
JP (4) JP5744856B2 (enExample)
KR (2) KR101441437B1 (enExample)
CN (1) CN102459603B (enExample)
AU (1) AU2010256753B2 (enExample)
BR (1) BRPI1010035A2 (enExample)
CA (1) CA2764370C (enExample)
DK (3) DK3279326T3 (enExample)
ES (2) ES2527173T3 (enExample)
HU (1) HUE038596T2 (enExample)
IL (1) IL216624A (enExample)
PL (3) PL2438171T3 (enExample)
SG (1) SG176251A1 (enExample)
TW (1) TWI513818B (enExample)
WO (1) WO2010141478A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
BRPI1010035A2 (pt) 2009-06-02 2015-08-25 Regeneron Pharma Células deficientes em fucosilação
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015057393A1 (en) * 2013-10-01 2015-04-23 University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
EP3149034B1 (en) * 2014-05-30 2022-07-13 New England Biolabs, Inc. Deglycosylation reagents and methods
CN106687581A (zh) * 2014-07-07 2017-05-17 塔尔加泽梅股份有限公司 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN108431026B (zh) * 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
EP3400241B1 (en) 2016-01-06 2020-07-22 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
SG11201807881VA (en) 2016-04-20 2018-10-30 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
KR102906454B1 (ko) * 2016-04-20 2026-01-02 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
KR102596303B1 (ko) * 2018-08-29 2023-10-30 유나이티드 바이오파마, 인크. 비푸코실화된 항체 및 그의 제조법
CA3118073A1 (en) 2018-10-29 2020-05-07 Immuno-Biological Laboratories Co., Ltd. Anti-hiv antibody and method for producing same
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2021242815A1 (en) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
JP2023528441A (ja) 2020-06-03 2023-07-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗SARS-CoV-2スパイク糖タンパク質抗体を用いてSARS-CoV-2感染及びCOVID-19を治療又は予防するための方法
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CA3212850A1 (en) 2021-06-22 2022-12-29 Frank DELFINO Anti-egfrviii antibody drug conjugates and uses thereof
CA3225575A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
AU2023228815A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
EP1888638A2 (en) 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level
JP5825756B2 (ja) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドXencor、 Inc. Cd19を標的とする最適化抗体
RU2479629C2 (ru) 2007-03-07 2013-04-20 Гликофи, Инк. Продукция гликопротеинов с модифицированным фукозилированием
ES2522615T3 (es) 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Regiones de expresión y estabilidad potenciadas
EP2311864A4 (en) 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd RECOMBINANT PROTEIN-S COMPOSITION
BRPI1010035A2 (pt) 2009-06-02 2015-08-25 Regeneron Pharma Células deficientes em fucosilação
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof

Also Published As

Publication number Publication date
EP3279326B1 (en) 2020-10-14
EP2808393B1 (en) 2018-01-10
ES2661074T3 (es) 2018-03-27
DK3279326T3 (da) 2020-12-21
TWI513818B (zh) 2015-12-21
US20210254022A1 (en) 2021-08-19
KR20120029443A (ko) 2012-03-26
PL2808393T3 (pl) 2018-04-30
WO2010141478A1 (en) 2010-12-09
EP2438171A1 (en) 2012-04-11
KR20140039340A (ko) 2014-04-01
AU2010256753B2 (en) 2013-11-28
US20170211115A1 (en) 2017-07-27
JP2016104045A (ja) 2016-06-09
TW201107469A (en) 2011-03-01
HUE038596T2 (hu) 2018-10-29
US9206455B2 (en) 2015-12-08
PL3279326T3 (pl) 2021-03-08
SG176251A1 (en) 2011-12-29
CN102459603B (zh) 2013-11-06
ES2527173T3 (es) 2015-01-21
US20200080124A1 (en) 2020-03-12
JP2015051021A (ja) 2015-03-19
DK2808393T3 (en) 2018-03-12
US8409838B2 (en) 2013-04-02
US20230295583A1 (en) 2023-09-21
EP2438171B1 (en) 2014-12-17
JP5744856B2 (ja) 2015-07-08
EP2808393A2 (en) 2014-12-03
US12054751B2 (en) 2024-08-06
EP2808393A3 (en) 2015-03-11
KR101641526B1 (ko) 2016-07-21
HK1163745A1 (en) 2012-09-14
JP2017006147A (ja) 2017-01-12
CA2764370C (en) 2018-08-21
HK1198180A1 (en) 2015-03-13
CA2764370A1 (en) 2010-12-09
US9550823B2 (en) 2017-01-24
US20100304436A1 (en) 2010-12-02
AU2010256753A1 (en) 2012-01-12
JP6211642B2 (ja) 2017-10-11
IL216624A (en) 2015-02-26
HK1249547A1 (en) 2018-11-02
US20130164786A1 (en) 2013-06-27
US10006070B2 (en) 2018-06-26
DK2438171T3 (en) 2015-01-26
JP2012528594A (ja) 2012-11-15
KR101441437B1 (ko) 2014-09-25
US20190024129A1 (en) 2019-01-24
US11560550B2 (en) 2023-01-24
PL2438171T3 (pl) 2015-04-30
IL216624A0 (en) 2012-02-29
US20160090410A1 (en) 2016-03-31
CN102459603A (zh) 2012-05-16
EP3279326A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
NL301265I1 (nl) Quizartinib
BRPI1010035A2 (pt) Células deficientes em fucosilação
DE112010004215A5 (de) Hydrostataktor
BRPI1014968A2 (pt) subalargador
DE112010004249A5 (de) Spindelaktor
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
EP2508411A4 (en) STRUCTURE
DK2506968T3 (da) Faujasit-zeolit
EP2454221A4 (en) cineole
FI20095852A0 (fi) Suuntaajalaite
EP2395565A4 (en) SOLAR CELL
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
DE112010002351A5 (de) Klemmorrichtung
EP2392475A4 (en) NECESSARY TO PAINT
BRPI0924276A2 (pt) célula galvânica
FI20096350A0 (fi) Tuloilmalaite
EP2492341A4 (en) PLURIPOTENT CELLS OF POSITIVE NESTINE
BR112012001230A2 (pt) célula galvânica
FI8691U1 (fi) Aukirullain
FI20096108A0 (fi) Järjestely
DE202009005065U8 (de) Kartonverschließmaschine
BRPI1015328A2 (pt) célula fotovoltaica
FI8782U1 (fi) Kulmakouruliitos
FI8660U1 (fi) Pilaripehmuste
BRPI0924006A2 (pt) estrutura

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time